MUSC Researchers Awarded $1.46M to Continue Study of Thoracic Aortic Aneurysms

Contact: Heather Woolwine
843-792-7669
woolwinh@musc.edu
 
Aug. 3, 2016

CHARLESTON, SC – Medical University of South Carolina researchers received a $1.46 million grant renewal to study how thoracic aortic aneurysms develop over time and how surgeons might be able to predict and stop development before the aorta ruptures, thereby saving the lives of patients with this disease. Initially funded by the National Institutes of Health in 2010, the study renewal will continue the work of principal investigator John Ikonomidis, M.D., Ph.D., Horace G. Smithy professor and MUSC Cardiothoracic Surgery chief.

Thoracic aortic aneurysm (TAA) is the bulging of the wall of the aorta, the largest artery in the body that carries oxygen-rich blood from the heart to the rest of the tissues and organs, weakening the vessel and enhancing the risk for rupture and subsequent death.

Current treatment options consist of surgical reconstruction or a minimally invasive intravascular procedure where an artificial tube is inserted through a large vessel in the leg, advanced into the aorta, and opened to eliminate the damaged portion of the aorta from the inside out. However, both options have significant limitations that do not address the underlying pathways that drive this devastating disease. According to Ikonomidis, better knowledge of the cellular events that lead to aneurysm formation may reveal novel treatment options for this condition, including region- specific gene therapy and targeted pharmacologic treatments.

“In the initial study, we showed how molecules within the wall of the aorta can destroy the aortic wall, causing the aneurysm,” he said. “Because there is no cure for this disease, the aim of the renewal of this NIH-funded study is to investigate these findings and focus on translating the discoveries into potential therapeutics.”

According to a 2012 Journal of Cardiac Surgery study co-authored by Ikonomidis, data have shown that the incidence of aneurysm development doubled between 1982 and 2002. When considering the aging Baby Boomer generation and medical advances increasing longevity, it is likely the incidence of TAA will continue to increase through the year 2050.

About MUSC

Founded in 1824 in Charleston, MUSC is the state's only comprehensive academic health system, with a unique mission to preserve and optimize human life in South Carolina through education, research and patient care. Each year, MUSC educates more than 3,200 students in six colleges – Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing, and Pharmacy – and trains more than 900 residents and fellows in its health system. MUSC brought in more than $300 million in research funds in fiscal year 2023, leading the state overall in research funding. MUSC also leads the state in federal and National Institutes of Health funding. Learn more about our academic programs.

As the health care system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest-quality and safest patient care while educating and training generations of outstanding health care providers and leaders to serve the people of South Carolina and beyond. Patient care is provided at 16 hospitals (includes owned or governing interest), with approximately 2,700 beds and four additional hospital locations in development, more than 350 telehealth sites and nearly 750 care locations situated in all regions of South Carolina. In 2023, for the ninth consecutive year, U.S. News & World Report named MUSC Health University Medical Center in Charleston the Number 1 hospital in South Carolina. Learn more about our patient services.

MUSC has a total enterprise annual operating budget of $5.9 billion. The nearly 26,000 MUSC family members include world-class faculty, physicians, specialty providers, scientists, students, affiliates and care team members who deliver groundbreaking education, research, and patient care.